Citadel Advisors
TECX

Citadel Advisors’s Tectonic Therapeutic TECX Stock Holding History

Citadel Advisors’s Portfolio TECX Stock Details TECX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-317,617
Closed -$7.82M – 14504
2025
Q4 		$6.63M Buy
317,617
+19,229
+6% +$357K ﹤0.01% 3854
2025
Q3 		$4.68M Buy
298,388
+133,342
+81% +$2.75M ﹤0.01% 4481
2025
Q2 		$3.28M Buy
165,046
+71,572
+77% +$1.45M ﹤0.01% 4829
2025
Q1 		$1.63M Buy
+93,474
New +$3.05M ﹤0.01% 5924
2024
Q2 		– Sell
-36,420
Closed -$559K – 15619
2024
Q1 		$559K Sell
36,420
-6,515
-15% -$103K ﹤0.01% 8131
2023
Q4 		$701K Buy
42,935
+436
+1% +$7.49K ﹤0.01% 7395
2023
Q3 		$785K Buy
42,499
+303
+0.7% +$5.36K ﹤0.01% 7074
2023
Q2 		$481K Hold
42,196
– – ﹤0.01% 8025
2023
Q1 		$506K Sell
42,196
-6,385
-13% -$88.9K ﹤0.01% 8281
2022
Q4 		$416K Buy
48,581
+5,899
+14% +$51.9K ﹤0.01% 8627
2022
Q3 		$329K Sell
42,682
-14,941
-26% -$166K ﹤0.01% 9362
2022
Q2 		$636K Buy
57,623
+6,121
+12% +$72.2K ﹤0.01% 8110
2022
Q1 		$816K Buy
51,502
+7,968
+18% +$165K ﹤0.01% 8181
2021
Q4 		$2.01M Sell
43,534
-46,493
-52% -$2.67M ﹤0.01% 6227
2021
Q3 		$6.03M Sell
90,027
-20,605
-19% -$1.69M ﹤0.01% 3954
2021
Q2 		$11.8M Sell
110,632
-9,888
-8% -$1.17M ﹤0.01% 2822
2021
Q1 		$18.4M Sell
120,520
-17,372
-13% -$2.83M ﹤0.01% 2081
2020
Q4 		$23.1M Sell
137,892
-14,909
-10% -$2.65M 0.01% 1652
2020
Q3 		$23.9M Sell
152,801
-4,006
-3% -$807K 0.01% 1422
2020
Q2 		$32.8M Sell
156,807
-6,083
-4% -$1.25M 0.01% 1089
2020
Q1 		$30.4M Buy
162,890
+22,230
+16% +$5.24M 0.01% 918
2019
Q4 		$34M Buy
140,660
+487
+0.3% +$93.9K 0.01% 1031
2019
Q3 		$23.8M Buy
140,173
+6,327
+5% +$1.43M 0.01% 1319
2019
Q2 		$26.1M Sell
133,846
-564
-0.4% -$122K 0.01% 1183
2019
Q1 		$35.6M Buy
134,410
+20,855
+18% +$3.81M 0.02% 890
2018
Q4 		$22.7M Sell
113,555
-10,723
-9% -$3.27M 0.01% 1129
2018
Q3 		$77.4M Sell
124,278
-25,115
-17% -$11.1M 0.03% 526
2018
Q2 		$51.2M Buy
+149,393
New +$53.9M 0.03% 688

Other funds holding TECX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors's TECX Position: Q1 2026 in Review

Citadel Advisors sold out of Tectonic Therapeutic (TECX) in Q1 2026, closing a stake of 317,617 shares — an estimated $7.82M sold.

Citadel Advisors first reported a position in TECX in Q2 2018 and held it in 28 quarters. The position peaked at $77.4M in Q3 2018. 111 funds tracked by Wall St. Rank hold TECX as of Q1 2026.

  • Citadel Advisors reported no remaining Tectonic Therapeutic position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 317,617 Tectonic Therapeutic shares in Q1 2026, an estimated $7.82M.
  • Citadel Advisors first reported a position in Tectonic Therapeutic in Q2 2018 and held it in 28 quarters.
  • Citadel Advisors's Tectonic Therapeutic position peaked at $77.4M in Q3 2018.
  • 111 funds tracked by Wall St. Rank held Tectonic Therapeutic as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.